{"disease":{"id":"advanced-solid-malignancies","name":"advanced solid malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03084471","title":"An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":867,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05417594","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":695,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04389541","title":"Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT02740985","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07136779","title":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"VelaVigo Bio Inc","has_results":false},{"nct_id":"NCT05315167","title":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":267,"lead_sponsor_name":"Zhuhai Yufan Biotechnologies Co., Ltd","has_results":false},{"nct_id":"NCT07299747","title":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":255,"lead_sponsor_name":"VelaVigo Bio Inc","has_results":false},{"nct_id":"NCT05735275","title":"A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":252,"lead_sponsor_name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07223047","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01058707","title":"Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05028478","title":"A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":164,"lead_sponsor_name":"Curon Biopharmaceutical (Australia) Co Pty Ltd","has_results":false},{"nct_id":"NCT03082209","title":"A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","has_results":false},{"nct_id":"NCT05690581","title":"Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT02000934","title":"A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":false},{"nct_id":"NCT03363893","title":"Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Carrick Therapeutics Limited","has_results":false},{"nct_id":"NCT05023486","title":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":121,"lead_sponsor_name":"Novita Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06224855","title":"A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Hangzhou DAC Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06649708","title":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd.","has_results":false},{"nct_id":"NCT07155811","title":"Lymphocyte Function Testing in Immuno-oncology","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT00979134","title":"Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03386526","title":"APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT02298387","title":"A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"OncoMed Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT01351350","title":"Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02141347","title":"Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04136834","title":"A Phase I Open-label Study for Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":62,"lead_sponsor_name":"Athenex, Inc.","has_results":false},{"nct_id":"NCT04989387","title":"Study of INCA 0186 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT04887870","title":"Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":false},{"nct_id":"NCT05126433","title":"Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT00529438","title":"RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07475559","title":"JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT06899061","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":41,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03568539","title":"IBI308 in Subjects With Advanced/Metastatic Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":true},{"nct_id":"NCT05159700","title":"A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":39,"lead_sponsor_name":"Zhuhai Yufan Biotechnologies Co., Ltd","has_results":false},{"nct_id":"NCT02398747","title":"Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01813474","title":"Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02350868","title":"Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Taipei Medical University","has_results":false},{"nct_id":"NCT03199586","title":"Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Novita Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02934568","title":"Ribociclib (LEE011) Rollover Study for Continued Access","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05338346","title":"A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Antengene Discovery Limited","has_results":false},{"nct_id":"NCT04854681","title":"Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05573724","title":"Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04353102","title":"A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Eucure (Beijing) Biopharma Co., Ltd","has_results":false},{"nct_id":"NCT06927297","title":"Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT05469919","title":"An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03394144","title":"Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03980821","title":"A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04094506","title":"Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT04214093","title":"A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06760481","title":"Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}